An observational study in Endocan, Copeptin and Serum, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2025-09-04.
Sponsored by Tanta University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.
Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.
Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.
Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.
191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.
This study's planned enrollment of 40 is below the median of 102 across 64 observational studies indexed under Diabetes Insipidus.
Browse Diabetes Insipidus studies →Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
This prospective study will be conducted at the Neonatal Intensive Care Unit (NICU), Pediatric Department, Tanta University Hospitals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neonates with gestational ages between 28 and 34 gestational weeks.
Diagnostic Test: Serum endocan · Diagnostic Test: Serum copeptin
Neonates with gestational ages between 34 and 36 gestational weeks.
Diagnostic Test: Serum endocan · Diagnostic Test: Serum copeptin
Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.
Serum endocan level for prediction of severity of respiratory distress syndrome
Serum endocan level for prediction of severity of respiratory distress syndrome (RDS) will be recorded.
Time frame: First day of life
Serum copeptin level for prediction of severity of respiratory distress syndrome
Serum copeptin level for the prediction of the severity of respiratory distress syndrome (RDS) will be recorded.
Time frame: 5th day of life
Serum endocan level for prediction of mortality
Serum endocan level for prediction of mortality will be recorded.
Time frame: First day of life
Serum copeptin level for prediction of mortality
Serum copeptin level for prediction of mortality will be recorded.
Time frame: 5th day of life
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
Time frame: After the end of study for one year.
Access criteria: The data will be available upon a reasonable request from the corresponding author.
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Nov 2025, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.